Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fujifilm Diosynth Biotechnologies Manufactures a New Licensed Biopharmaceutical

Published: Thursday, November 15, 2012
Last Updated: Thursday, November 15, 2012
Bookmark and Share
ThromboGenics' has received FDA approval for the launch of JETREA® in the USA.

Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA® (ocriplasmin) in the USA for the treatment of Symptomatic Vitreomacular Adhesion (VMA).

The two companies announced a long-term commercial supply agreement for manufacture of the bulk substance in September 2010 when the product had completed its Phase III trials and have worked together to complete validation and establish a well characterized process.

Fujifilm Diosynth Biotechnologies is one of the world's leading providers of contract process development and manufacturing services for biopharmaceuticals and the UK business has been working with ThromboGenics for over seven years as the drug progressed through its clinical trials.

This illustrates the value of long-term deep collaboration in securing both cost effective and timely commercialization of such complex new medicines.

Steve Bagshaw, Managing Director of Fujifilm Diosynth Biotechnologies' Billingham, UK, said "we are delighted that ThromboGenics has received FDA approval for the launch of JETREA® in the USA. It is very gratifying for our team to see that their hard work in developing and manufacturing the product over the years has resulted in a drug being available to people suffering from distressing ophthalmic conditions. This is fifth licensed biopharmaceutical manufactured by Fujifilm Diosynth Biotechnologies and the second made at our Billingham site, demonstrating our growing expertise in helping to transition biopharmaceuticals from the clinic to become marketed new drugs".

Dr. Patrik De Haes, CEO of ThromboGenics said "Fujifilm Diosynth Biotechnologies has been a key partner in helping to bring our first drug to market. Their team at Billingham have done an excellent job in developing and validating a robust process and manufacturing material to enable us to launch the product on schedule".


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FUJIFILM Completes Acquisition of Kalon Biotherapeutics
Acquisition enhances Texas’ growing reputation as a global biotechnology leader.
Friday, December 19, 2014
Fujifilm Diosynth Biotechnologies Continues Expansion of R&D Facilities
Company invests more than US$5.6M in new laboratories and equipment.
Wednesday, June 25, 2014
Fujifilm Diosynth Biotechnologies’ UK Site Receives Renewed Manufacturing Licence
Licence authorizes commercial manufacturing at the company’s Billingham, UK site.
Thursday, October 10, 2013
Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare
Strategic alliance for the production of antibody drug conjugates.
Thursday, October 25, 2012
Fujifilm Diosynth Expands R&D Capabilities at its Billingham, UK Site
Company has completed the first phase of a $4.5m investment in new equipment and laboratories.
Friday, April 06, 2012
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!